PDF herunterladen
Arzneimittelforschung 2009; 59(10): 504-512
DOI: 10.1055/s-0031-1296434
Otologic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Therapeutic Properties and Tolerance of Procaine and Phenazone Containing Ear Drops in Infants and Very Young Children

Dieter Adam
1   University Clinic for Children and Children’s Outpatient Department at Dr. von Hauner’s Children’s Hospital, Munich, (Germany)
,
Pierre Federspil
2   ENT Department and Outpatient Department of the University of Homburg/Saar, (Germany)
,
Martin Lukes
3   ENT Practice, Freilassing, (Germany)
,
Otto Petrowicz
4   Klinikum rechts der Isar, Technical University, Munich, (Germany)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Dezember 2011 (online)

    Lizenzen und Reprints

Abstract

Since ear pain is often intolerable in very young children with acute otitis media (AOM), a safe pain reduction is indispensable both from the medical as well as from the ethical point of view.

Methods:

To confirm the safety and therapeutic properties of ear drops (Otalgan®) consisting of the short acting local anesthetic procaine hydrochloride (CAS 51-05-8) and the anti-inflammatory component phenazone (CAS 60-80-0), a multi-center, non-interventional post marketing surveillance (PMS) study was performed in 428 children (f/m: 45.6%/54.4%) aged between 0 and 6 years (mean 3.44 ys). Otalgia as the overall diagnostic criterion present in all children was allotted to otitis media in 398 (93%) and to otitis externa in 28 patients (6.5%), while in two patients, both diagnoses were documented.

Results:

No adverse drug reactions (ADR) to the target medication have been detected during the entire study. The evaluation of tolerance by the physicians (mean score 1.38) and by the children/parents (mean score 1.48) was in compliance with the absence of ADR. The drug tolerance was rated by the physicians in 99.8% of the cases as very good (62.2%; n = 266) or good (37.6%; n = 161). In one child (0.2%), the tolerance was evaluated by the physician as moderate. The judgement of parents revealed for all children either a very good (51.9%; n = 222) or good (48.1%; n = 206) evaluation of tolerance. The target medication was tolerated well, independent of the duration of treatment (2 to 10 days with a median of 5 days), of the daily dose and of the accumulated dose per treatment cycle, i. e. longer treatments and higher doses were not associated with a worsening of tolerance evaluations. Even in the highest dose class of over 100 drops per treatment cycle, no changes of tolerance could be revealed. As far as can be derived from non-controlled observational data, the results also confirm the known efficacy profile of the target medication in children. Under the treatment, the initial mean pain score of 2.33 was reduced by nearly 93% down to 0.17, accompanied by a corresponding normalization of the otoscopic findings of the ear canal and the tympanic membrane, and by the improvement of the general condition. In 95.3% of the children, the physicians rated the efficacy of the target medication as very good (n = 156; 36.4%) or good (n = 252; 58.9%) while in 14 patients (3.3%) the efficacy was scored as moderate, in 4 patients (0.9%) as minimal and in two patients as inadequate (0.5%). The results also demonstrate that with the use of the target medication for local symptomatic treatment of pain in the outer ear canal and in AOM in children, the use of antibiotics in most of the cases can be avoided.

Conclusions:

The findings are in full accordance with the results of former clinical studies, with positive evaluations of ototoxicity and with accumulated pharmacovigilance data showing that since introduction of the drug in 1911, no ADR have ever been reported in children. The study confirms that the target medication provides a safe and rapid pain reduction and improvement of inflammation in very young children suffering from painful acute inflammatory ear conditions.

Key words

Acute otitis media - Anesthetic ear drops - CAS 51-05-8 - CAS 60-80-0 - Children - Otalgan® - Phenazone - Procaine hydrochloride
 

  • References

  • 1 Grzegorowski M, Szydlowski J. Acute otitis media in children. Pol Merkuriusz Lek. 2005; 19: 494-6
    PubMedGoogle Scholar
  • 2 Blomgren K, Pohjavuori S, Poussa T, Hatakka K, Korpela R, Pitkaranta A. Effect of accurate diagnostic criteria on incidence of acute otitis media in otitis-prone children. Scand J Infect Dis. 2004; 36: 6-9
    CrossrefPubMedGoogle Scholar
  • 3 Garces-Sanchez M, Diez-Domingo J, Alvarez de Labiada T, Planelles V, Graullera M, Baldo JM et al. Epidemiology and burden of acute otitis media in Valencia (Spain). An Pediatr (Barc). 2004; 60: 125-32
    CrossrefPubMedGoogle Scholar
  • 4 Ross AK, Croft PR, Collins M. Incidence of acute otitis media in infants in a general practice. J R Coll Gen Pract. 1988; 38: 70-2
    PubMedGoogle Scholar
  • 5 Froom J, Culpepper L, Grob P, Bartelds A, Bowers P, Bridges-Webb C et al. Diagnosis and antibiotic treatment of acute otitis media: report from International Primary Care Network. BMJ. 1990; 300: 582-6
    CrossrefPubMedGoogle Scholar
  • 6 Bondy J, Berman S, Glazner J, Lezotte D. Direct expenditures related to otitis media diagnoses: extrapolations from a pediatric medicaid cohort. Pediatrics. 2000; 105: E72
    CrossrefPubMedGoogle Scholar
  • 7 Taylor PS, Faeth I, Marks MK, Del Mar CB, Skull SA, Pezzullo ML et al. Cost of treating otitis media in Australia. Expert Rev Pharmacoecon Outcomes Res. 2009; 9: 133-41
    CrossrefPubMedGoogle Scholar
  • 8 Federspil P, Federspil PA. Antibiotic therapy in oto-rhino-laryngology. HNO. 2005; 53: 11-28
    CrossrefPubMedGoogle Scholar
  • 9 Federspil P [Guidelines of the German society of oto-rhino-laryngology][head and neck surgery for the use of antibiotics in head and throat infections] 2008 AWMF-Leitlinien-Register Nr. 017/066.
    PubMed
  • 10 Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989; 160: 83-94
    CrossrefPubMedGoogle Scholar
  • 11 Leibovitz E, Greenberg D. Acute otitis media in children: current epidemiology, microbiology, clinical manifestations, and treatment. Chang Gung Med J. 2004; 27: 475-88
    PubMedGoogle Scholar
  • 12 Prasad S, Ewigman B. Use anesthetic drops to relieve acute otitis media pain. J Fam Pract. 2008; 57: 370-3
    PubMedGoogle Scholar
  • 13 Vogt WE. [Final report – Post-marketing surveillance study of Otalgan ear drops in children and adolescents]. Internal Report Study no. 021KLI98. Berlin: Biopharm GmbH; 1999
    Google Scholar
  • 14 Kraft K, Loew D, Schneider B, Kemper FH. Planning][realization and evaluation of post-marketing surveillance studies. Recommendations of the Society for Phytotherapy. Arzneimittelforschung. 1997; 47: 990-4
    PubMedGoogle Scholar
  • 15 German Federal Institute for Drugs and Medical Devices (BfArM). [Guideline for the planning][conduct and evaluation of post-marketing surveillance studies]. 12 Nov 1998
    PubMedGoogle Scholar
  • 16 Rahlfs VW. clinical study report. Clinical study with local anesthetics and glycerol containing preparations for topical application in the ear. Gauting (Germany): idv Data Analysis and Study Planning. 2004; 003KLI95: 1
    PubMedGoogle Scholar
  • 17 Bolt P, Barnett P, Babl FE, Sharwood LN. Topical ligno-caine for pain relief in acute otitis media: results of a double-blind placebo-controlled randomised trial. Arch Dis Child. 2008; 93: 40-4
    CrossrefPubMedGoogle Scholar
  • 18 Delb W, Federspil P. Hör-, Sprach- u. Stimmstörungen. In Sitzmann FC. editor. Pädiatrie. 3rd ed. Stuttgart: Georg Thieme Verlag; 2007: 933-947
    Google Scholar
  • 19 Plasschaert AI, Rovers MM, Schilder AG, Verheij TJ, Hak E. Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995–2003. Pediatrics. 2006; 117: 1879-86
    CrossrefPubMedGoogle Scholar
  • 20 Johnson NC, Holger JS. Pediatric acute otitis media: the case for delayed antibiotic treatment. J Emerg Med. 2007; 32: 279-84
    CrossrefPubMedGoogle Scholar
  • 21 AAP. American Academy of Pediatrics: The assessment and management of acute pain in infants, children, and adolescents. Pediatrics. 2001; 108: 793-7
    CrossrefPubMedGoogle Scholar
  • 22 CPS. Canadian Paediatric Society: Antibiotic Management of Acute Otitis Media, Index of Position Statements from the Infectious Diseases and Immunization Committee. Paediatr Child Health. 1998; 3 (4) 265-7
    PubMedGoogle Scholar
  • 23 Adam D. Antibiotic therapy of ENT infections – How resistant are our pathogens?. HNO-Nachrichten. 2004; 5: 28-32
    PubMedGoogle Scholar
  • 24 Koopman L, Hoes AW, Glasziou PP, Appelman CL, Burke P, McCormick DP et al. Antibiotic therapy to prevent the development of asymptomatic middle ear effusion in children with acute otitis media –a meta-analysis of individual patient data. Arch Otolaryngol Head Neck Surg. 2008; 134: 128-32
    CrossrefPubMedGoogle Scholar
  • 25 Hyams JS, Feder Jr. H, Krause PJ, Frick J, McLaughlin JC, Furth T, Hine P. Occurrence of Clostridium difficile toxinassociated gastroenteritis following antibiotic therapy for otitis media in young children. Pediatr Infect Dis. 1984; 3: 433-6
    PubMedGoogle Scholar
  • 26 Cohen ML. Epidemiology of drug resistance – implications for a post-antimicrobial era. Science. 1992; 257: 1050-5
    CrossrefPubMedGoogle Scholar
  • 27 Sanders S, Glasziou PP, Del Mar CB, Rovers M. Antibiotics for acute otitis media in children (Review). Cochrane Library. (Issue 2) CD000219, pub. 2 2009;
    PubMedGoogle Scholar
  • 28 Granstrom G. “Wait-and-see” in acute otitis media. An effective method for antibiotics use reduction – but a follow up is necessary. Lakartidningen. 2006; 103: 3798
    PubMedGoogle Scholar
  • 29 Siegel RM, Kiely M, Bien JP, Joseph EC, Davis JB, Mendel SG et al. Treatment of otitis media with observation and a safety-net antibiotic prescription. Pediatrics. 2003; 112: 527-31
    CrossrefPubMedGoogle Scholar
  • 30 Marchetti F, Ronfani L, Nibali SC, Tamburlini G. Delayed prescription may reduce the use of antibiotics for acute otitis media: a prospective observational study in primary care. Arch Pediatr Adolesc Med. 2005; 159: 679-84
    CrossrefPubMedGoogle Scholar
  • 31 Spiro DM, Arnold DH. The concept and practice of a wait-and-see approach to acute otitis media. Curr Opin Pediatr. 2008; 20: 72-8
    CrossrefPubMedGoogle Scholar
  • 32 Lacy SM. Writing a wait-and-see prescription for the treatment of acute otitis media may decrease the use of antibiotics. J Pediatr. 2007; 150: 319
    PubMedGoogle Scholar
  • 33 Shahroor S, Shvil Y, Ohali M, Granot E. Acetaminophen toxicity in children as a “therapeutic misadventure”. Harefuah. 2000; 138: 654-710
    PubMedGoogle Scholar